Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

23. oktober 2014 opdateret af: Boehringer Ingelheim

A Double-blind, Randomised, 3-way Cross-over Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin ER Extended Release (ER) 200 mg Dipyridamole/25 mg ASA Formulations in Healthy Male and Female Volunteers

Comparative pharmacokinetics of dipyridamole in two new formulations of Asasantin ER compared to the present commercial formulation

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

18

Fase

  • Fase 1

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 50 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • All participants in the study should be healthy males or females, range from 21 to 50 years of age and be within ± 20 % of their normal weight (Broca-Index)
  • Prior to admission to the study all volunteers will have given, in accordance with good clinical practice (GCP) and the local legislation, their written informed consent
  • Subsequently each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead ECG
  • Hematopoietic, hepatic and renal function tests will be carried out in the laboratory
  • The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations
  • The above mentioned examinations will be performed within 14 days before the first administration of the test substance

Exclusion Criteria:

  • Volunteers are excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
  • Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Subjects with diseases of the central nervous system (such as epilepsy) or with psychiatric or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Subjects with chronic or relevant acute infections
  • Subjects with allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Volunteers who have taken a drug with a long half-life (≥ 24 hours) within one month or less than ten half-lives of the respective drug before enrolment in the study
  • Volunteers who receive any other drugs which might influence the results of the trial during the week previous to enrolment in the study
  • Volunteers who participate in another study with an investigational drug within the last two months preceding the study
  • Volunteers who are unable to refrain from smoking on study days
  • Volunteers who smoke more than10 cigarettes (or equivalent) per day
  • Volunteers who drink more than 60 g of alcohol per day
  • Volunteers who are dependent on drugs
  • Volunteers who donate blood (≥ 100 mL) within the last four weeks
  • Volunteers who participate in excessive physical activities within the last week before the study (e.g. competitive sports)
  • Volunteers who suffer from any other disease or abnormality of clinical relevance
  • History of hemorrhagic diatheses
  • History of gastro-intestinal ulcer, perforation or bleeding
  • History of bronchial asthma
  • History of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency

Female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception (adequate contraception e.g. sterilization, intrauterine devices (IUD), oral contraceptives)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Asasantin ER, nuværende kommerciel formulering
Eksperimentel: Asasantin ER, new formulation I
Eksperimentel: Asasantin ER, new formulation II

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Area under the concentration-time curve of dipyridamole in plasma at steady state (AUC,ss)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Percent peak trough fluctuation of dipyridamole in plasma (%PTF)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration

Sekundære resultatmål

Resultatmål
Tidsramme
Maximum concentration of the analytes in plasma at steady state (Cmax,ss)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Minimum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Time from dosing to the maximum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ Time from dosing to the maximum measured concentration of the analytes in plasma at steady state (tmax,ss)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Percent area under the curve fluctuation of the analytes in plasma (AUCfluct)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Terminal half-life of the analytes in plasma (t1/2)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Percent of dose of the analytes recovered unchanged in urine (Ae%)
Tidsramme: Up to 24 hours after start of drug administration
Up to 24 hours after start of drug administration
Ratio of peak concentration of the analytes in plasma over area under the curve at steady state (Cmax,ss / AUC,ss)
Tidsramme: Up to 48 hours after start of drug administration
Up to 48 hours after start of drug administration
Number of subjects with clinically relevant changes in vital signs (blood pressure, pulse rate)
Tidsramme: up to 8 days after last study drug administration
up to 8 days after last study drug administration
Number of subjects with clinically relevant changes in 12-lead ECG
Tidsramme: up to 8 days after last study drug administration
up to 8 days after last study drug administration
Number of subjects with clinically relevant changes in laboratory values
Tidsramme: up to 8 days after last study drug administration
up to 8 days after last study drug administration
Number of subjects with adverse events
Tidsramme: up to 8 days after last study drug administration
up to 8 days after last study drug administration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. april 2001

Primær færdiggørelse (Faktiske)

1. maj 2001

Datoer for studieregistrering

Først indsendt

23. oktober 2014

Først indsendt, der opfyldte QC-kriterier

23. oktober 2014

Først opslået (Skøn)

24. oktober 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

24. oktober 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. oktober 2014

Sidst verificeret

1. oktober 2014

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 9.144

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

3
Abonner